Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
World game at war: why some European nations have threatened a World Cup boycott 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
LAKE FOREST, Ill., May 07, 2018 -- Depomed, Inc. (NASDAQ:DEPO) today announced that members of senior management will participate at the 2018 UBS Global Healthcare Conference in a session scheduled for 1:30 pm ET on Tuesday, May 22, 2018 in New York, NY.
This presentation will be webcast and can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcasts will be archived for 30 days.
About Depomed
Depomed is a leading specialty pharmaceutical company committed to putting the patient first in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain businesses and its emerging Orphan Specialty Business is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACTS:
John B. Thomas
SVP, Investor Relations and Corporate Communications
[email protected]
